Blockage of JNK pathway enhances arsenic trioxide-induced apoptosis in human keratinocytes

Toxicology and Applied Pharmacology

Volumn 244, Issue 2, 2010, Pages 234-241

  Huang, Huei Sheng ^a   Liu, Zi Miao ^a   Hong, Duang Yang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Arsenic trioxide; Keratinocyte; P21WAF1 CIP1; TGIF

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARSENIC TRIOXIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 1; HOMEODOMAIN PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; KERATINOCYTE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTHRACENES; APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KERATINOCYTES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 8; OXIDES; PHOSPHORYLATION;

EID: 77950058429     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.12.037     Document Type: Article

References (52)

1. Bartholin L., Powers S.E., Melhuish T.A., Lasse S., Weinstein M., Wotton D. TGIF inhibits retinoid signaling. Mol. Cell. Biol. 2006, 26:990-1001.
2. Behrens A., Jochum W., Sibilia M., Wagner E.F. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 2000, 19:2657-2663.
3. Bode A.M., Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 2002, 42:5-24.
4. Borlak J., Meier T., Halter R., Spanel R., Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005, 24:1809-1819.
5. Burglin T.R. Analysis of TALE superclass homeobox genes (MEIS, PBC, KNOX, Iroquois, TGIF) reveals a novel domain conserved between plants and animals. Nucleic Acids Res. 1997, 25:4173-4180.
6. Chen C.J., Wang S.L., Chiou J.M., Tseng C.H., Chiou H.Y., Hsueh Y.M., Chen S.Y., Wu M.M., Lai M.S. Arsenic and diabetes and hypertension in human populations: a review. Toxicol. Appl. Pharmacol. 2007, 222:298-304.
7. Chen L.C., Chen B.K., Chang W.C. Activating protein 1-mediated cyclooxygenase-2 expression is independent of N-terminal phosphorylation of c-Jun. Mol. Pharmacol. 2005, 67:2057-2069.
8. Cruzalegui F.H., Hardingham G.E., Bading H. c-Jun functions as a calcium-regulated transcriptional activator in the absence of JNK/SAPK1 activation. EMBO J. 1999, 18:1335-1344.
9. Cuzick J., Evans S., Gillman M., Price Evans D.A. Medicinal arsenic and internal malignancies. Br. J. Cancer 1982, 45:904-911.
10. Datto M.B., Yu Y., Wang X.F. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 1995, 270:28623-28628.
11. Denicourt C., Dowdy S.F. Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev. 2004, 18:851-855.
12. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M., Davis R.J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994, 76:1025-1037.
13. Dilda P.J., Hogg P.J. Arsenical-based cancer drugs. Cancer Treat Rev. 2007, 33:542-564.
14. Efferth T., Li P.C., Konkimalla V.S., Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 2007, 13:353-361.
15. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
16. Gripp K.W., Wotton D., Edwards M.C., Roessler E., Ades L., Meinecke P., Richieri-Costa A., Zackai E.H., Massague J., Muenke M., Elledge S.J. Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination. Nat. Genet. 2000, 25:205-208.
17. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
18. Huang H.S., Chang W.C., Chen C.J. Involvement of reactive oxygen species in arsenite-induced downregulation of phospholipid hydroperoxide glutathione peroxidase in human epidermoid carcinoma A431 cells. Free Radic. Biol. Med. 2002, 33:864-873.
19. WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity. J. Biomed. Sci. 2006, 13:113-125.
20. Jares-Erijman E.A., Jovin T.M. FRET imaging. Nat. Biotechnol. 2003, 21:1387-1395.
21. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 1997, 9:240-246.
22. Lei K., Nimnual A., Zong W.X., Kennedy N.J., Flavell R.A., Thompson C.B., Bar-Sagi D., Davis R.J. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol. Cell. Biol. 2002, 22:4929-4942.
23. Liao W.T., Chang K.L., Yu C.L., Chen G.S., Chang L.W., Yu H.S. Arsenic induces human keratinocyte apoptosis by the FAS/FAS ligand pathway, which correlates with alterations in nuclear factor-kappa B and activator protein-1 activity. J. Invest. Dermatol. 2004, 122:125-129.
24. Liu B., Pan S., Dong X., Qiao H., Jiang H., Krissansen G.W., Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 2006, 97:675-681.
25. WAF1/CIP1 expression in human epidermoid carcinoma A431 cells. Cell. Signal. 2006, 18:244-255.
26. WAF1/CIP1 expression. Toxicol. Appl. Pharmacol. 2008, 233:297-307.
27. WAF1/CIP1 expression. J. Biomed. Sci. 2008, 15:333-342.
28. Lo R.S., Wotton D., Massague J. Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO J. 2001, 20:128-136.
29. Mar L., Hoodless P.A. Embryonic fibroblasts from mice lacking Tgif were defective in cell cycling. Mol. Cell. Biol. 2006, 26:4302-4310.
30. Melhuish T.A., Wotton D. The interaction of the carboxyl terminus-binding protein with the Smad corepressor TGIF is disrupted by a holoprosencephaly mutation in TGIF. J. Biol. Chem. 2000, 275:39762-39766.
31. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62:3893-3903.
32. Murgo A.J. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001, 6(Suppl. 2):22-28.
33. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87:953-959.
34. Waf1/Cip1 immunolocalization in multiple myeloma. Biomed. Res. 2005, 26:91-98.
35. Pessah M., Prunier C., Marais J., Ferrand N., Mazars A., Lallemand F., Gauthier J.M., Atfi A. c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6198-6203.
36. Seo S.R., Ferrand N., Faresse N., Prunier C., Abecassis L., Pessah M., Bourgeade M.F., Atfi A. Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF-beta signaling. Mol. Cell 2006, 23:547-559.
37. Sharma M., Sun Z. 5′TG3′ interacting factor interacts with Sin3A and represses AR-mediated transcription. Mol. Endocrinol. 2001, 15:1918-1928.
38. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
39. Smeal T., Binetruy B., Mercola D.A., Birrer M., Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 1991, 354:494-496.
40. Soucy N.V., Ihnat M.A., Kamat C.D., Hess L., Post M.J., Klei L.R., Clark C., Barchowsky A. Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol. Sci. 2003, 76:271-279.
41. Straub A.C., Stolz D.B., Vin H., Ross M.A., Soucy N.V., Klei L.R., Barchowsky A. Low level arsenic promotes progressive inflammatory angiogenesis and liver blood vessel remodeling in mice. Toxicol. Appl. Pharmacol. 2007, 222:327-336.
42. Tse W.P., Cheng C.H., Che C.T., Lin Z.X. Arsenic trioxide, arsenic pentoxide, and arsenic iodide inhibit human keratinocyte proliferation through the induction of apoptosis. J. Pharmacol. Exp. Ther. 2008, 326:388-394.
43. Wang C.H., Hsiao C.K., Chen C.L., Hsu L.I., Chiou H.Y., Chen S.Y., Hsueh Y.M., Wu M.M., Chen C.J. A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol. Appl. Pharmacol. 2007, 222:315-326.
44. Weiss R.H., Borowsky A.D., Seligson D., Lin P.Y., Dillard-Telm L., Belldegrun A.S., Figlin R.A., Pantuck A.D. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J. Urol. 2007, 177:63-68. discussion 68-69.
45. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 2007, 19:142-149.
46. Whitmarsh A.J., Davis R.J. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene 2007, 26:3172-3184.
47. Wotton D., Lo R.S., Lee S., Massague J. A Smad transcriptional corepressor. Cell 1999, 97:29-39.
48. Wotton D., Lo R.S., Swaby L.A., Massague J. Multiple modes of repression by the Smad transcriptional corepressor TGIF. J. Biol. Chem. 1999, 274:37105-37110.
49. Wotton D., Knoepfler P.S., Laherty C.D., Eisenman R.N., Massague J. The Smad transcriptional corepressor TGIF recruits mSin3. Cell Growth Differ. 2001, 12:457-463.
50. Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer Res. 2004, 10:3815-3824.
51. Yu H.S., Lee C.H., Jee S.H., Ho C.K., Guo Y.L. Environmental and occupational skin diseases in Taiwan. J. Dermatol. 2001, 28:628-631.
52. Yu H.S., Liao W.T., Chai C.Y. Arsenic carcinogenesis in the skin. J. Biomed. Sci. 2006, 13:657-666.